• Efficiency of using antifungal drugs in women with vaginal candidiasis on the background of papillomavirus infection

Efficiency of using antifungal drugs in women with vaginal candidiasis on the background of papillomavirus infection

PERINATOLOGY AND PEDIATRIC. UKRAINE. 2018.2(74):31-34; doi 10.15574/PP.2018.74.31

Gorbunova O. V., Zarichanska H. V.
Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

According to the sources, vaginal candidiasis develops on the background of papillomavirus infection in 36–41% of cases. The violation of the vaginal biocenosis decreases the immunological potential of the epithelium, and creates favourable conditions for the carcinogenic effect of the human papillomavirus. We have examined 100 patients (18–40 years old) in order to evaluate the efficiency and safeness of Fluzamed (active ingredient: Fluconazole-150 mg) usage in treatment of vulvovaginal candidiasis with cervical dysplasia caused by papillomavirus infection. The treatment control was performed three times: after the first course of treatment, in 3 and 6 months. The study has shown that due to Fluconazole-150 mg treatment, the disease recurrences at 3 and 6 months were occurred significantly rarely as compared to the cases of Butoconazole-20 mg/g application. The complete eradication of PVI was clinically and laboratory confirmed after 3 and 6 months of treatment. In our study, we have confirmed the safety of a systemic drug Fluzamed (active ingredient: Fluconazole-150 mg) usage by the lack of adverse reactions after its administration.
Key words: vaginal candidiasis, papillomavirus infection, Fluzamed.

References

1. Voronenko Y.V., Shekera O.G., Vdovychenko Y.P. (2016). Topical issues of obstetrics in the practice of a family doctor. Manual for intern doctors and doctors-students of institutions (faculties) of postgraduate education. Edited by Y.V. Voronenko, O.G. Shekera, Y.P. Vdovychenko. «Family Medicine» series. Кyiv.: Publisher O.Y. Zaslavskyi: 346.

2. Portal Consilium Medicum: http://con_med.ru/magazines/gynecology/gynecology-03-2002/bakterialnyy_vaginoz_i_papillomavirusnaya_infektsiya/?t_fieldset=SOCSERV

3. Kira E.F., Muslimova S.Z. (2008). Nonspecific vaginitis and its effect on the reproductive health of a woman (literature review). Reproduction problems. 5: 8–13.

4. Radzinskyi V.E., Khamoshina M.B., Kaigorodova L.A. at al. (2014). Correction of violations of the biocenosis of the vagina: march in place or moving forward? Reproductive Endocrinology. 4(18): 92–100.

5. Donders G.G., Bellen G., Mendling W. (2010). Management of reccurent vulvovaginal candidosis as a chronic illness. Gynec Obstet Inv. 4(70): 234–249.

6. Ravel J., Gajer P., Abdo Z. et al. (2011). Vaginal microbiome of reproductive-age women. Proc Natl Acad Scien USA. 108; 1: 4680–7. https://doi.org/10.1073/pnas.1002611107; PMid:20534435 PMCid:PMC3063603